Efficacy of the levonorgestrel intrauterine system (LNG-IUS) in the prevention of the atypical endometrial hyperplasia and endometrial cancer: retrospective data from selected obese menopausal symptomatic women

References

• Montgomery BE, Daum GS, Dunton CJ. Endometrial hyperplasia: a review. Obstet Gynecol Surv 2004;59:368–378.
   PubMed Web of Science ®Google Scholar
• Hunter JE, Tritz DE, Howell MG, DePriest PD, Gallion HH, Andrews SJ, Buckley SB, et al. The prognostic and therapeutic implications of cytologic atypia in patients with endometrial hyperplasia. Gynecol Oncol 1994;55:66–71.
   PubMed Web of Science ®Google Scholar
• Anderson JN, Peck EJ Jr, Clark JH. Estrogen-induced uterine responses and growth: relationship to receptor estrogen binding by uterine nuclei. Endocrinology 1975;96:160–167.
   PubMed Web of Science ®Google Scholar
• King RJ, Whitehead MI, Campbell S, Minardi J. Effect of estrogen and progestin treatments on endometria from postmenopausal women. Cancer Res 1979;39:1094–1101.
   PubMed Web of Science ®Google Scholar
• Soliman PT, Oh JC, Schmeler KM, Sun CC, Slomovitz BM, Gershenson DM, Burke TW, Lu KH. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol 2005;105:575–580.
   PubMed Web of Science ®Google Scholar
• Lacey JV Jr, Sherman ME, Rush BB, Ronnett BM, Ioffe OB, Duggan MA, Glass AG, et al. Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. J Clin Oncol 2010;28:788–792.
   PubMed Web of Science ®Google Scholar
• Epplein M, Reed SD, Voigt LF, Newton KM, Holt VL, Weiss NS. Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history. Am J Epidemiol 2008;168:563–70; discussion 571.
   PubMed Web of Science ®Google Scholar
• Viola AS, Gouveia D, Andrade L, Aldrighi JM, Viola CF, Bahamondes L. Prevalence of endometrial cancer and hyperplasia in non-symptomatic overweight and obese women. Aust N Z J Obstet Gynaecol 2008;48:207–213.
   PubMed Web of Science ®Google Scholar
• Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. Cancer 1985;56:403–412.
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol 2005;106:413–425.
   PubMedGoogle Scholar
• Mansour D. Modern management of abnormal uterine bleeding: the levonorgestrel intra-uterine system. Best Pract Res Clin Obstet Gynaecol 2007;21:1007–1021.
   PubMed Web of Science ®Google Scholar
• Wildemeersch D, Janssens D, Pylyser K, De Wever N, Verbeeck G, Dhont M, Tjalma W. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up. Maturitas 2007;57:210–213.
   PubMed Web of Science ®Google Scholar
• Wildemeersch D, Dhont M. Treatment of nonatypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system. Am J Obstet Gynecol 2003;188:1297–1298.
   PubMed Web of Science ®Google Scholar
• Varma R, Soneja H, Bhatia K, Ganesan R, Rollason T, Clark TJ, Gupta JK. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia–a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol 2008;139:169–175.
   PubMed Web of Science ®Google Scholar
• Wan YL, Holland C. The efficacy of levonorgestrel intrauterine systems for endometrial protection: a systematic review. Climacteric 2011;14:622–632.
   PubMed Web of Science ®Google Scholar
• Vilos GA, Marks J, Tureanu V, Abu-Rafea B, Vilos AG. The levonorgestrel intrauterine system is an effective treatment in selected obese women with abnormal uterine bleeding. J Minim Invasive Gynecol 2011;18:75–80.
   PubMed Web of Science ®Google Scholar
• Leslie KK, Thiel KW, Yang S. Endometrial cancer: potential treatment and prevention with progestin-containing intrauterine devices. Obstet Gynecol 2012;119:419–420.
   PubMed Web of Science ®Google Scholar
• ROGERS J, MITCHELL GW Jr. The relation of obesity to menstrual disturbances. N Engl J Med 1952;247:53–55.
   PubMed Web of Science ®Google Scholar
• Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 2002;11:1531–1543.
   PubMed Web of Science ®Google Scholar
• Matteson KA, Abed H, Wheeler TL 2nd, Sung VW, Rahn DD, Schaffer JI, Balk EM; Society of Gynecologic Surgeons Systematic Review Group. A systematic review comparing hysterectomy with less-invasive treatments for abnormal uterine bleeding. J Minim Invasive Gynecol 2012;19:13–28.
   PubMed Web of Science ®Google Scholar
• Lethaby AE, Cooke I, Rees M. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev 2005;4:CD002126.
   PubMedGoogle Scholar
• Kresowik J, Ryan GL, Van Voorhis BJ. Progression of atypical endometrial hyperplasia to adenocarcinoma despite intrauterine progesterone treatment with the levonorgestrel-releasing intrauterine system. Obstet Gynecol 2008;111:547–549.
   PubMed Web of Science ®Google Scholar
• Andersson K, Stadberg E, Mattsson LA, Rybo G, Samsioe G. Intrauterine or oral administration of levonorgestrel in combination with estradiol to perimenopausal women – effects on lipid metabolism during 12 months of treatment. Int J Fertil Menopausal Stud 1996;41:476–483.
   PubMedGoogle Scholar
• Suvanto-Luukkonen E, Kauppila A. The levonorgestrel intrauterine system in menopausal hormone replacement therapy: five-year experience. Fertil Steril 1999;72:161–163.
   PubMed Web of Science ®Google Scholar
• Varila E, Wahlström T, Rauramo I. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril 2001;76:969–973.
   PubMed Web of Science ®Google Scholar
• Hampton NR, Rees MC, Lowe DG, Rauramo I, Barlow D, Guillebaud J. Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women. Hum Reprod 2005;20:2653–2660.
   PubMed Web of Science ®Google Scholar